Physician agency and patient survival

作者: Mireille G. Jacobson , Tom Y. Chang , Craig C. Earle , Joseph P. Newhouse

DOI: 10.1016/J.JEBO.2016.11.011

关键词:

摘要: We investigate the role of physician agency in determining health care supply and patient outcomes. show that an increase due to a change private incentives has theoretically ambiguous impact on welfare. The can reflect either induced demand for ineffective or reduction prior rationing effective care. Furthermore, market structure matters welfare effects changes incentives. then analyze Medicare fees caused physicians their provision chemotherapy. find this treatment improved survival, extending median life expectancy lung cancer patients by about 18%. Consistent with model, we while response was larger less concentrated markets, survival improvements were more markets.

参考文章(43)
Patrick Mullen, The arrival of average sale price. Biotechnology healthcare. ,vol. 4, pp. 48- 53 ,(2007)
Joeëlle Y. Friedman, Lesley H. Curtis, Bradley G. Hammill, Jatinder K. Dhillon, Charles H. Weaver, Sugata Biswas, Amy P. Abernethy, Kevin A. Schulman, The Medicare Modernization Act and reimbursement for outpatient chemotherapy: do patients perceive changes in access to care? Cancer. ,vol. 110, pp. 2304- 2312 ,(2007) , 10.1002/CNCR.23042
Thomas G. McGuire, Chapter 9 – Physician Agency* Handbook of Health Economics. ,vol. 1, pp. 461- 536 ,(2000) , 10.1016/S1574-0064(00)80168-7
Erin M Johnson, M Marit Rehavi, None, Physicians Treating Physicians: Information and Incentives in Childbirth American Economic Journal: Economic Policy. ,vol. 8, pp. 115- 141 ,(2016) , 10.1257/POL.20140160
James H. Stock, Mark W. Watson, Introduction to Econometrics ,(2002)
Paul Heaton, Eric A. Helland, Does Treatment Respond to Reimbursement Rates? Evidence from Trauma Care Social Science Research Network. ,(2008) , 10.2139/SSRN.1335022
G. M. Strauss, J. Herndon, M. A. Maddaus, D. W. Johnstone, E. A. Johnson, D. M. Watson, D. J. Sugarbaker, R. L. Schilsky, M. R. Green, Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633 Journal of Clinical Oncology. ,vol. 22, pp. 7019- 7019 ,(2004) , 10.1200/JCO.2004.22.14_SUPPL.7019
John Akscin, Thomas R. Barr, Elaine L. Towle, Key Practice Indicators in Office-Based Oncology Practices: 2007 Report on 2006 Data Journal of Oncology Practice. ,vol. 3, pp. 200- 203 ,(2007) , 10.1200/JOP.0743001
Vahakn B. Shahinian, Yong-Fang Kuo, Scott M. Gilbert, Reimbursement Policy and Androgen-Deprivation Therapy for Prostate Cancer New England Journal of Medicine. ,vol. 363, pp. 1822- 1832 ,(2010) , 10.1056/NEJMSA0910784
Carrie H. Colla, Nancy E. Morden, Jonathan S. Skinner, J. Russell Hoverman, Ellen Meara, Impact of Payment Reform on Chemotherapy at the End of Life Journal of Oncology Practice. ,vol. 8, pp. e6s- e13s ,(2012) , 10.1200/JOP.2012.000539